Literature DB >> 15519745

Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease.

Asad Vaisi Raygani1, Mahine Zahrai, Akbar Soltanzadeh, Mahmood Doosti, Ebrahim Javadi, Tayebeh Pourmotabbed.   

Abstract

Recent studies indicate that there is a synergic association between butyrylcholinesterase-K variant (BChE-K) and apolipoproteinE-epsilon 4 (ApoE-epsilon 4) to promote risk for Alzheimer's disease (AD). Most subsequently replicative studies have been unable to confirm these finding. We attempted to replicate this finding in 105 AD cases and age and sex matched 129 controls from Tehran population, Iran. The BChE genotype of patients were found to be significantly different from controls (chi(2) = 12.2, d.f. = 2, p = 0.002). The frequency of BChE-K allele was also found to differ significantly in cases compared to controls [24% versus 12% (chi(2) = 20.6, d.f. = 2, p < 0.001)] leading to an increased risk of AD in subjects with this allele (OR = 2.5, 95% CI = 1.64-3.8, p = 0.001). This risk was found to increase from (OR = 2.37, 95% CI = 1.3-4.2, p = 0.006) in subjects less than 75 years old to (OR = 3.16, 95% CI = 1.41-7.1, p = 0.001) in subjects 75 years and older. But, the ApoE-epsilon 4 allele association risk was found to decrease from (OR = 9.5, 95% CI = 3.74-24.1, p = 0.001) in subjects <75 years to (OR = 1.36, 95% CI = 0.49-4.1, p = 0.58) in those subjects 75 years and older. Furthermore, we found a very strong synergic association between BChE-K and ApoE-epsilon 4 OR = 19.1 (95% CI = 428-85.45, p < 0.001). In spite of this, synergism decreased from OR = 36.2 (95% CI = 4.4-296, p = 0.001) in subjects <75 year olds to OR = 6.2 (95% CI = 0.9-72.4, p = 0.06) in subjects > or =75 years. We have found that BChE-K and ApoE-epsilon 4 alleles act synergistically to increase the risk of the late-onset AD, particularly in age group <75 years in Tehran, Iran.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15519745     DOI: 10.1016/j.neulet.2004.08.057

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  13 in total

Review 1.  Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.

Authors:  Gohar Mushtaq; Nigel H Greig; Jalaluddin A Khan; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

2.  Association of BDNF and BCHE with Alzheimer's disease: Meta-analysis based on 56 genetic case-control studies of 12,563 cases and 12,622 controls.

Authors:  Huihui Ji; Dongjun Dai; Yunliang Wang; Danjie Jiang; Xingyu Zhou; Peipei Lin; Xiaosui Ji; Jinfeng Li; Yuzheng Zhang; Honglei Yin; Rongrong Chen; Lina Zhang; Mingqing Xu; Shiwei Duan; Qinwen Wang
Journal:  Exp Ther Med       Date:  2015-03-03       Impact factor: 2.447

3.  Association of Matrix Metalloproteinase-2 (MMP-2) and MMP-9 Promoter Polymorphisms, Their Serum Levels, and Activities with Coronary Artery Calcification (CAC) in an Iranian Population.

Authors:  Saeed Elahirad; Daniel Elieh Ali Komi; Amir Kiani; Ehsan Mohammadi-Noori; Asad Vaisi-Raygani; Hadi Mozafari; Fariborz Bahrehmand; Mohammadreza Saidi; Vahid Toupchi-Khosroshahi; Nahid Salehi
Journal:  Cardiovasc Toxicol       Date:  2021-11-03       Impact factor: 3.231

4.  BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia.

Authors:  Alessandra Bizzarro; V Guglielmi; R Lomastro; A Valenza; A Lauria; C Marra; M C Silveri; F D Tiziano; C Brahe; C Masullo
Journal:  J Neural Transm (Vienna)       Date:  2010-03       Impact factor: 3.575

5.  Butyrylcholinesterase K variant and the APOE-epsilon 4 allele work in synergy to increase the risk of coronary artery disease especially in diabetic patients.

Authors:  Asad Vaisi-Raygani; Zohreh Rahimi; Haidar Tavilani; Tayebeh Pourmotabbed
Journal:  Mol Biol Rep       Date:  2009-08-15       Impact factor: 2.316

6.  A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.

Authors:  Agneta Nordberg; Clive Ballard; Roger Bullock; Taher Darreh-Shori; Monique Somogyi
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-07

Review 7.  The diabetic brain and cognition.

Authors:  Peter Riederer; Amos D Korczyn; Sameh S Ali; Ovidiu Bajenaru; Mun Seong Choi; Michael Chopp; Vesna Dermanovic-Dobrota; Edna Grünblatt; Kurt A Jellinger; Mohammad Amjad Kamal; Warda Kamal; Jerzy Leszek; Tanja Maria Sheldrick-Michel; Gohar Mushtaq; Bernard Meglic; Rachel Natovich; Zvezdan Pirtosek; Martin Rakusa; Melita Salkovic-Petrisic; Reinhold Schmidt; Angelika Schmitt; G Ramachandra Sridhar; László Vécsei; Zyta Beata Wojszel; Hakan Yaman; Zheng G Zhang; Tali Cukierman-Yaffe
Journal:  J Neural Transm (Vienna)       Date:  2017-08-01       Impact factor: 3.575

8.  Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.

Authors:  Sophie Sokolow; Xiaohui Li; Lucia Chen; Kent D Taylor; Jerome I Rotter; Robert A Rissman; Paul S Aisen; Liana G Apostolova
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.160

9.  Alzheimer's disease and type 2 diabetes mellitus: the cholinesterase connection?

Authors:  Gumpeny Ramachandra Sridhar; Hanuman Thota; Appa Rao Allam; Changalasetty Suresh Babu; Akula Siva Prasad; Ch Divakar
Journal:  Lipids Health Dis       Date:  2006-11-11       Impact factor: 3.876

10.  Butyrylcholinesterase K variant and Alzheimer's disease risk: a meta-analysis.

Authors:  Zongcheng Wang; Yuren Jiang; Xi Wang; Yangsen Du; Dandan Xiao; Youchao Deng; Jinlian Wang
Journal:  Med Sci Monit       Date:  2015-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.